Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy

Genetically modified bacteria have been engineered as a tool to deliver bioactive proteins to mucosal tissues as a means to exert both local and systemic effects. They have an excellent safety profile, the result of years of human consumption in the food industry, as well as a lack of toxicity and i...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 8; p. 1961
Main Authors Cook, Dana P, Gysemans, Conny, Mathieu, Chantal
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Genetically modified bacteria have been engineered as a tool to deliver bioactive proteins to mucosal tissues as a means to exert both local and systemic effects. They have an excellent safety profile, the result of years of human consumption in the food industry, as well as a lack of toxicity and immunogenicity. Also, containment strategies have been developed to promote further application as clinical protein-based therapeutics. Here, we review technological advancements made to enhanced the potential of as live biofactories and discuss some examples of tolerogenic immunotherapies mediated by mucosal drug delivery . Additionally, we highlight their use to induce mucosal tolerance by targeted autoantigen delivery to the intestine as an approach to reverse autoimmune type 1 diabetes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Specialty section: This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Reviewed by: Femke Broere, Utrecht University, Netherlands; Joan Stein-Streilein, Schepens Eye Research Institute, United States
Edited by: Luis Graça, Universidade de Lisboa, Portugal
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2017.01961